PriceTargets.com logo

Encompass Health - EHC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $143.86
  • Forecasted Upside: 46.74%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$98.04 As of 06/17/2026 04:59 PM ET
▼ -1.803 (-1.81%)

This chart shows the closing price for EHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Encompass Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EHC

Analyst Price Target is $143.86
▲ +46.74% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is $143.86, with a high forecast of $160.00 and a low forecast of $125.00. The average price target represents a 46.74% upside from the last price of $98.04.

This chart shows the closing price for EHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Encompass Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2026
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2026

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/8/2026Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
5/28/2026TD CowenInitiated CoverageBuy$125.00
5/22/2026Leerink PartnersSet Target$152.00
5/5/2026BarclaysLower TargetOverweight ➝ Overweight$153.00 ➝ $140.00
2/6/2026BarclaysBoost TargetOverweight ➝ Overweight$150.00 ➝ $153.00
11/19/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/31/2025Raymond James FinancialUpgradeStrong-Buy
10/30/2025BarclaysBoost TargetOverweight ➝ Overweight$141.00 ➝ $150.00
10/21/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/8/2025Weiss RatingsReiterated RatingBuy (B+) ➝ Buy (B+)
10/2/2025UBS GroupBoost TargetBuy ➝ Buy$140.00 ➝ $150.00
9/27/2025Weiss RatingsReiterated RatingBuy (B+) ➝ Buy (B+)
9/16/2025KeyCorpBoost TargetOverweight ➝ Overweight$135.00 ➝ $140.00
9/10/2025Bank of AmericaBoost TargetBuy ➝ Buy$145.00 ➝ $160.00
8/14/2025Truist FinancialBoost TargetBuy ➝ Buy$135.00 ➝ $140.00
8/6/2025UBS GroupBoost TargetBuy ➝ Buy$130.00 ➝ $140.00
6/5/2025StephensUpgradeOverweight ➝ Strong-Buy$135.00
5/27/2025KeyCorpBoost TargetOverweight ➝ Overweight$122.00 ➝ $135.00
4/28/2025UBS GroupBoost TargetBuy ➝ Buy$117.00 ➝ $130.00
4/28/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$110.00 ➝ $125.00
4/28/2025Truist FinancialReiterated RatingBuy ➝ Buy$116.00 ➝ $135.00
4/25/2025KeyCorpBoost TargetOverweight ➝ Overweight$120.00 ➝ $122.00
4/25/2025BarclaysBoost TargetOverweight ➝ Overweight$118.00 ➝ $129.00
2/11/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$110.00 ➝ $110.00
2/10/2025KeyCorpBoost TargetOverweight ➝ Overweight$117.00 ➝ $120.00
2/7/2025BarclaysBoost TargetOverweight ➝ Overweight$116.00 ➝ $118.00
2/7/2025William BlairReiterated RatingOutperform
10/30/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$105.00 ➝ $110.00
10/30/2024Truist FinancialReiterated RatingBuy ➝ Buy$108.00 ➝ $116.00
10/29/2024BarclaysBoost TargetOverweight ➝ Overweight$109.00 ➝ $116.00
10/29/2024KeyCorpBoost TargetOverweight ➝ Overweight$115.00 ➝ $117.00
10/14/2024Truist FinancialBoost TargetBuy ➝ Buy$104.00 ➝ $108.00
10/11/2024KeyCorpInitiated CoverageOverweight$115.00
10/10/2024KeyCorpUpgradeStrong-Buy
9/26/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$95.00 ➝ $105.00
9/25/2024UBS GroupBoost TargetBuy ➝ Buy$100.00 ➝ $110.00
8/15/2024Truist FinancialBoost TargetBuy ➝ Buy$100.00 ➝ $104.00
8/8/2024UBS GroupBoost TargetBuy ➝ Buy$96.00 ➝ $100.00
8/6/2024StephensReiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00
8/6/2024BarclaysLower TargetOverweight ➝ Overweight$113.00 ➝ $109.00
7/15/2024Truist FinancialBoost TargetBuy ➝ Buy$95.00 ➝ $100.00
7/10/2024BarclaysBoost TargetOverweight ➝ Overweight$108.00 ➝ $113.00
7/10/2024Leerink PartnersUpgradeStrong-Buy
7/10/2024Leerink PartnersInitiated CoverageOutperform$100.00
6/5/2024StephensReiterated RatingOverweight ➝ Overweight$94.00 ➝ $94.00
5/22/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$83.00 ➝ $95.00
4/26/2024Raymond James FinancialReiterated RatingStrong-Buy ➝ Strong-Buy$85.00 ➝ $95.00
4/25/2024BarclaysBoost TargetOverweight ➝ Overweight$101.00 ➝ $108.00
4/25/2024MizuhoBoost TargetBuy ➝ Buy$93.00 ➝ $95.00
3/28/2024BarclaysBoost TargetOverweight ➝ Overweight$95.00 ➝ $101.00
3/6/2024BarclaysInitiated CoverageOverweight$95.00
2/9/2024Truist FinancialBoost TargetBuy ➝ Buy$82.00 ➝ $86.00
2/9/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$83.00
2/9/2024MizuhoBoost TargetBuy ➝ Buy$77.00 ➝ $82.00
2/7/2024William BlairReiterated RatingOutperform
1/16/2024StephensReiterated RatingOverweight ➝ Overweight$85.00
9/28/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$83.00
8/8/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$70.00 ➝ $83.00
8/4/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$76.00 ➝ $80.00
8/3/2023Raymond James FinancialBoost TargetStrong-Buy ➝ Strong-Buy$80.00 ➝ $85.00
8/3/2023Truist FinancialBoost TargetBuy ➝ Buy$75.00 ➝ $82.00
8/3/2023MizuhoBoost TargetBuy ➝ Buy$74.00 ➝ $77.00
8/3/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$61.00 ➝ $71.00
7/20/2023StephensReiterated RatingOverweight ➝ Overweight$78.00
6/29/2023StephensBoost Target$74.00 ➝ $78.00
5/2/2023Royal Bank Of CanadaBoost Target$66.00 ➝ $70.00
5/1/2023Deutsche Bank AktiengesellschaftBoost Target$70.00 ➝ $73.00
5/1/2023MizuhoBoost Target$69.00 ➝ $74.00
4/28/2023Bank of AmericaBoost Target$69.00 ➝ $74.00
4/4/2023BarclaysBoost TargetEqual Weight$57.00 ➝ $61.00
3/14/2023BarclaysInitiated CoverageEqual Weight$57.00
2/9/2023Deutsche Bank AktiengesellschaftBoost Target$62.00 ➝ $70.00
2/9/2023Truist FinancialBoost TargetBuy$70.00 ➝ $75.00
2/9/2023MizuhoBoost TargetBuy$65.00 ➝ $69.00
2/9/2023Credit Suisse GroupBoost TargetOutperform$62.00 ➝ $73.00
2/8/2023UBS GroupBoost Target$68.00 ➝ $73.00
2/8/2023StephensReiterated RatingOverweight$70.00
10/28/2022StephensLower TargetOverweight$60.00 ➝ $58.00
10/28/2022Raymond James FinancialBoost TargetStrong-Buy$65.00 ➝ $72.00
9/21/2022Credit Suisse GroupLower TargetOutperform$63.00 ➝ $62.00
8/24/2022Royal Bank Of CanadaLower Target$82.00 ➝ $66.00
8/9/2022Credit Suisse GroupLower Target$63.00
8/8/2022Truist FinancialLower TargetBuy$75.00 ➝ $65.00
8/4/2022Raymond James FinancialLower TargetStrong-Buy$70.00 ➝ $65.00
8/4/2022BMO Capital MarketsLower TargetOutperform$83.00 ➝ $65.00
8/4/2022BarclaysLower TargetOverweight$80.00 ➝ $63.00
8/3/2022Deutsche Bank AktiengesellschaftLower Target$80.00 ➝ $62.00
6/21/2022Truist FinancialLower TargetBuy$85.00 ➝ $75.00
6/21/2022StephensLower TargetOverweight$78.00 ➝ $74.00
6/17/2022Raymond James FinancialLower Target$85.00 ➝ $70.00
6/10/2022Credit Suisse GroupLower TargetOutperform$83.00 ➝ $82.00
6/8/2022Royal Bank Of CanadaLower Target$85.00 ➝ $82.00
4/7/2022Truist FinancialBoost Target$78.00 ➝ $85.00
2/7/2022Raymond James FinancialLower TargetStrong-Buy$90.00 ➝ $80.00
2/3/2022Credit Suisse GroupLower Target$84.00 ➝ $77.00
1/20/2022Deutsche Bank AktiengesellschaftLower Target$95.00 ➝ $80.00
11/3/2021MizuhoLower TargetBuy$94.00 ➝ $80.00
11/2/2021Raymond James FinancialLower TargetStrong-Buy$107.00 ➝ $90.00
11/1/2021BMO Capital MarketsLower TargetOutperform$102.00 ➝ $75.00
10/29/2021Deutsche Bank AktiengesellschaftLower TargetBuy$110.00 ➝ $95.00
10/13/2021Truist FinancialLower TargetBuy$100.00 ➝ $88.00
9/23/2021UBS GroupInitiated CoverageBuy$98.00
8/2/2021Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$95.00 ➝ $107.00
7/29/2021Royal Bank Of CanadaBoost TargetOutperform$102.00 ➝ $104.00
7/29/2021Credit Suisse GroupBoost TargetOutperform$96.00 ➝ $98.00
7/29/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$104.00 ➝ $110.00
7/2/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$87.00 ➝ $104.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

1.41 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 2 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 34 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 34 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Encompass Health logo
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions. It offers services through the Medicare program to federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. The company was incorporated in 1984 and is based in Birmingham, Alabama.
Read More

Today's Range

Now: $98.04
Low: $96.43
High: $99.45

50 Day Range

MA: $104.40
Low: $99.13
High: $108.43

52 Week Range

Now: $98.04
Low: $92.77
High: $127.99

Volume

806,091 shs

Average Volume

1,072,571 shs

Market Capitalization

$9.73 billion

P/E Ratio

16.37

Dividend Yield

0.76%

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Encompass Health?

The following sell-side analysts have issued stock ratings on Encompass Health in the last twelve months: Bank of America Corporation, Barclays PLC, KeyCorp, Leerink Partners, Raymond James Financial, Inc., TD Cowen, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for EHC.

What is the current price target for Encompass Health?

0 Wall Street analysts have set twelve-month price targets for Encompass Health in the last year. Their average twelve-month price target is $143.86, suggesting a possible upside of 46.7%. Bank of America Corporation has the highest price target set, predicting EHC will reach $160.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $125.00 for Encompass Health in the next year.
View the latest price targets for EHC.

What is the current consensus analyst rating for Encompass Health?

Encompass Health currently has 1 hold rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EHC will outperform the market and that investors should add to their positions of Encompass Health.
View the latest ratings for EHC.

What other companies compete with Encompass Health?

Other companies that are similar to Encompass Health include Alcon, Tenet Healthcare, Universal Health Services, The Ensign Group and Brookdale Senior Living. Learn More about companies similar to Encompass Health.

How do I contact Encompass Health's investor relations team?

Encompass Health's physical mailing address is 3660 Grandview Pkwy Ste 200, BIRMINGHAM, AL 35243-3332, United States. The company's listed phone number is (205) 967-7116 and its investor relations email address is [email protected]. The official website for Encompass Health is www.healthsouth.com. Learn More about contacing Encompass Health investor relations.